Ziarco is an independent, clinical stage biotechnology company progressing novel & differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery.

Our current focus is on chronic, inflammatory skin diseases, specifically atopic dermatitis and psoriasis. ZPL-3893787 is a once-daily oral antagonist of the most recently characterised histamine receptor, H4R, which we will advance into Phase 2 patient studies during 2015. ZPL-5212372 is a potent, long-acting, topical inhibitor of cPLA2, which is anticipated to reach patients in 2016.

Ziarco’s compounds are ideally positioned to address the unmet needs in many disease states. Our programmes are distinctive yet share key over-arching characteristics: new mechanism small molecules which will safely suppress steroid-unresponsive inflammation and represent significant advances in medical therapy. Ziarco’s approach is to advance our programmes in therapeutic indications where evidence of differentiation can be clearly demonstrated at early times during clinical development.

Our highly-experienced team, who invented and developed these programmes, is passionately committed to advancing them and delivering new medicines with outstanding profiles of efficacy and safety.